Pacira Pharmaceuticals (NSDQ:PCRX) said today that it has signed a deal to acquire Myoscience and its pain relief device for up to $220 million. Myoscience’s iovera system is designed to safely freeze nerves while protecting surrounding tissue. As part of the deal that is slated to close by early April, Pacira plans to incorporate the iovera system into […]
The opioid epidemic is one of the deadliest problems facing the U.S. today. Through the development of new pain management devices, medtech could be a leader in solving the crisis. The prescription opioid overdose crisis in America didn’t start until the late 1990s, when pharmaceutical companies touted prescription painkillers that weren’t supposed to be addictive. […]
Opioid-related deaths have become an epidemic in the U.S., garnering attention from the White House, the FDA and many other governmental bodies. From 2000 to 2014, nearly half a million Americans died from drug overdoses. In 2015, more than 50,000 people died from drug overdoses, and 33,000 were opioid-related. Prescription overdoses continue to cause more […]
Myoscience said today it launched a clinical trial aiming to investigate its Iovera pain management system in treating post-surgical knee patients, with the 1st patient enrolled at Memphis, Tenn.’s Campbell Clinic. Many of the patients are recommended to go to this pain management clinic to receive the right treatment afterwards. The Fremont, Calif.-based company’s Iovera […]
Myoscience said today it won FDA 510(k) clearance for its Iovera device designed to relieve pain and symptoms associated with knee osteoarthritis. The Fremont, Calif.-based company’s Iovera technology is a non-opioid and non-systemic treatment designed to block pain signals from the peripheral nerves. Myoscience said the Iovera treatment uses the body’s natural response to cold […]
September 29, 2014 by Alexander Soule
Myoscience said it landed $8.4 million of a hoped-for $11.5 million for a device that applies extreme cold to the skin as a way to temporarily treat pain and smooth wrinkles.
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.